Cholesterol Numbers Explained: LDL, HDL, Triglycerides and What Actually Matters

Heart Health · 4 · March 6, 2026

You get your bloodwork back. Total cholesterol: 210. Your doctor says it's "a bit high." But that single number tells you almost nothing useful. The lipid panel has four components, and they matter in very different ways. Some cardiologists have started saying they don't even look at total cholesterol anymore. Here's what they look at instead.

LDL: The Number That Drives Treatment Decisions

Low-density lipoprotein cholesterol is the primary target. It's the particle that infiltrates arterial walls, gets oxidized, triggers inflammation, and builds plaque. The relationship between LDL and cardiovascular events is causal, dose-dependent, and time-dependent. A 2019 meta-analysis of 26 statin trials and 4 non-statin trials — covering 170,000 patients — published in The Lancet found that every 1 mmol/L (roughly 39 mg/dL) reduction in LDL reduced major cardiovascular events by 21%.

For the average healthy adult, an LDL below 100 mg/dL is considered optimal. If you've already had a heart attack or have established cardiovascular disease, the target drops to below 70 mg/dL. Some aggressive guidelines now suggest below 55 mg/dL for very high-risk patients — a threshold supported by the FOURIER and ODYSSEY trials using PCSK9 inhibitors.

Here's what matters: lower is better. The "lower is better" hypothesis was confirmed by Mendelian randomization studies — people born with genetically low LDL have proportionally lower lifetime cardiovascular risk. There's no threshold below which LDL stops being beneficial to reduce.

HDL: Not the Protective Shield We Thought

High-density lipoprotein cholesterol was long called "good cholesterol." The idea was that HDL particles transport cholesterol away from arteries back to the liver — reverse cholesterol transport. Higher HDL meant more cleanup. An HDL above 60 mg/dL was considered cardioprotective.

But then the drug trials came. Torcetrapib, dalcetrapib, and evacetrapib all raised HDL dramatically — and none reduced cardiovascular events. Torcetrapib actually increased deaths. The 2023 analysis of UK Biobank data in JAMA Cardiology added another twist: very high HDL (above 80 mg/dL) was associated with increased mortality. The relationship is U-shaped, not linear.

Most cardiologists now consider HDL a useful marker but not a treatment target. Low HDL (below 40 for men, below 50 for women) signals metabolic risk, but raising it artificially hasn't helped.

Triglycerides: The Overlooked Risk Factor

Triglycerides are the fat circulating in your blood after meals. Normal is below 150 mg/dL. Above 200 is high. Above 500 raises the risk of pancreatitis on top of cardiovascular risk. Fasting triglycerides above 150 mg/dL independently predict coronary events, even when LDL is controlled.

The REDUCE-IT trial showed that high-dose icosapent ethyl (purified EPA, a fish oil derivative) reduced major cardiovascular events by 25% in patients with elevated triglycerides already on statins. This was a 2019 NEJM publication that reshaped how we think about residual cardiovascular risk beyond LDL.

Triglycerides respond dramatically to lifestyle changes. Cutting refined carbohydrates and sugar, limiting alcohol, losing even 5-10% of body weight, and exercising regularly can drop triglycerides by 30-50% without medication.

Beyond the Standard Panel: ApoB and Lp(a)

Apolipoprotein B (ApoB) measures the actual number of atherogenic particles in your blood — every LDL, VLDL, and intermediate density particle carries one ApoB molecule. Some experts argue ApoB is a better predictor than LDL because two people with the same LDL can have very different particle counts. The European Atherosclerosis Society endorsed ApoB measurement in their 2024 consensus statement.

Lipoprotein(a) — Lp(a) — is a genetically determined particle that increases cardiovascular and aortic valve disease risk. It's inherited, doesn't change with lifestyle, and affects about 20% of the population at high levels. You should have it tested once in your lifetime. If it's elevated (above 50 mg/dL), your LDL target should be more aggressive. The first Lp(a)-lowering drug (muvalaplin) is in phase 3 trials as of early 2026.

Key Takeaways

- LDL is the primary treatment target — every 39 mg/dL reduction cuts cardiovascular events by 21%

- HDL is not a treatment target: raising it with drugs hasn't reduced events, and very high HDL may be harmful

- Elevated triglycerides are an independent risk factor — lifestyle changes can reduce them by 30-50%

- Ask your doctor about ApoB and Lp(a) for a more complete risk picture — Lp(a) should be tested once in your life

- Total cholesterol alone is nearly meaningless — always look at the breakdown

Get a personalized cardiac risk score that incorporates your lipid numbers and other factors with our risk assessment tool.